Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:05:05 2026-02-12 am EST			5-day change	1st Jan Change
920.95 ^INR	+2.52%		+1.73%	+0.72%

Feb. 11	India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment	RE
Feb. 11	Zydus Lifesciences enters settlement agreement with Astellas over Myrbetriq	RE

Zydus Lifesciences signs agreement with Myriad Genetics for cancer-risk tests in India

Published on 12/18/2025 at 11:31 pm EST

Reuters

Latest news about Zydus Lifesciences Limited

Feb. 11	India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment	RE
Feb. 11	Zydus Lifesciences enters settlement agreement with Astellas over Myrbetriq	RE
Feb. 11	Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,100 From INR1,130, Keeps at Buy	MT
Feb. 10	Zydus Lifesciences Limited, Q3 2026 Earnings Call, Feb 10, 2026
Feb. 09	India's Aurobindo Pharma posts higher profit on steady domestic demand	RE
Feb. 09	India's Stocks Rise on Monday as Trade Deal Clarity Boosts Investor Appetite	MT
Feb. 09	Zydus Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
Feb. 09	Zydus Lifesciences' Net Profit Rises in Fiscal Q3; Shares Up 4%	MT
Feb. 09	India's Zydus Life posts surprise profit rise on strong North American sales	RE
Feb. 09	Zydus Lifesciences Q3 consol net profit 10.42 billion rupees	RE
Feb. 08	Diary - India economic, corporate events on February 9	RE
Feb. 05	Drugmaker Alembic Pharma posts earnings dip on Indian labour code changes	RE
Feb. 04	Zydus Lifesciences receives tentative approval from USFDA for dapagliflozin tablets	RE
Feb. 04	Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Dapagliflozin Tablets, 5 Mg and 10 Mg	CI
Jan. 23	Indian Companies Receive Approval for Generic Versions of Wegovy and Ozempic	FW
Jan. 23	Zydus Lifesciences says USFDA inspection closed with 2 observations for Ankleshwar unit-2 plant	RE
Jan. 22	Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesity-drug race	RE
Jan. 22	Zydus Lifesciences Launches Nivolumab Biosimilar in India	MT
Jan. 21	Zydus Lifesciences launches biosimilar of Nivolumab in India	RE
Jan. 21	Zydus Lifesciences Limited Launches Biosimilar of Nivolumab, Tishtha	CI
Jan. 20	Zydus Lifesciences Reportedly Eyes Acquisition of Ardelyx for $2.5 Billion	CI
Jan. 15	Agenus Falls After $141 Million Zydus Deal Closes	DJ
Jan. 15	Agenus Announces Closing of $141 Million Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness	CI
Jan. 15	Zydus Lifesciences Limited Receives Final Approval from USFDA for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg	CI
Jan. 15	Zydus Lifesciences Gets US FDA's Final Nod for Platelet Deficiency Drug	MT

Chart Zydus Lifesciences Limited

Duration

Period

ZYDUSLIFE: Dynamic Chart

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Employees

27,917

Sector

Pharmaceuticals

Calendar

May. 14 - Q4 2026 Earnings Release (Projected)

More about the company